AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Posterior Nasal Nerve Combined With Anterior Ethmoid Neurotomy for Idiopathic Rhinitis

RecruitingNAAges 18 Years - 65 YearsAllXu Yu
💬

In plain words

What the trial is, and whether it could suit you

The present study was a prospective, parallel controlled, multicentre clinical study. The trial was divided into two groups, the posterior nasal nerve combined with anterior ethmoid neurotomy group (group A) and the standardized drug treatment group (group B). Patients with idiopathic rhinitis (IR) who met the inclusion criteria were included in a 7-day introductory period of nasal spray hormone (Rhinocort®) treatment. Subjects with IR who remained eligible after the introductory period were prospectively assigned to Group A or Group B through a standardized shared decision-making process based on clinical suitability and participant preference. Participants were followed for 1 year after treatment assignment. In group A, subjects will undergo the posterior nasal nerve combined with anterior ethmoid neurotomy. In group B, subjects will be treated with medication according to guideline re

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: 1. Patients signed the free and informed consent form and understood the explanation of the study. 2. patients with IR between 18 and 65 years and their body mass index (BMI) should be ≥19 kg/m2 and ≤24 kg/m2. 3. Patients diagnosed with idiopathic rhinitis (IR)that were defined as nonsmoking patients with at least 2 nasal complaints of nasal obstruction, rhinorrhea, itching, and/or sneezing for more than 1 hour a day and for more than 1 year. 4. Patients with negative skin prick test (SPT) responses or sIgE 5. Nasal cytological exam with eosinophilia less than 20%. 6. Patients had a Total Nasal Symptom Score (TNSS) of ≥6 and a subscore of nasal discharge ≥2 and a subscore of nasal congestion ≥1. Exclusion Criteria: 1. Patients with colored secretions, inflammation,nasal polyps, chronic sinusitis, nasal tumours. 2. Patients with other chronic rhinitis such as occupational rhinitis, drug rhinitis, gustatory rhinitis, hormonal rhinitis, atrophic rhinitis, etc. 3. Patients with anatomic nasal abnormalities responsible for nasal symptoms. 4. Patients with nasal/sinus surgery 3 months before the study. 5. Patients with severe mental illness. 6. Patients with uncontrolled asthma, systemic disorders or malignancies. 7. Patients with history of chronic smoking, substance abuse, drug use, and/or excessive alcohol consumption. 8. Patients in pregnancy or lactation.
💊

What it tests

  • Posterior nasal nerve combined with anterior ethmoid neurotomy
  • Drug therapy group
📍

Where

2 sites
Renmin Hospital of Wuhan University
Wuhan, China
Renmin Hospital of Wuhan University
Wuhan, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy